Congressional committees urged the Food and Drug Administration to “take swift action” to ensure that any future Alzheimer's approvals aren’t met with “the same doubts about the integrity of FDA’s review" of Biogen's Aduhelm.



from Section Page News - Modern Healthcare https://ift.tt/gvYV6D5
via IFTTT